BRPI0415858A - compostos de medicamentos terapêuticos modificados por tocoferol - Google Patents

compostos de medicamentos terapêuticos modificados por tocoferol

Info

Publication number
BRPI0415858A
BRPI0415858A BRPI0415858-0A BRPI0415858A BRPI0415858A BR PI0415858 A BRPI0415858 A BR PI0415858A BR PI0415858 A BRPI0415858 A BR PI0415858A BR PI0415858 A BRPI0415858 A BR PI0415858A
Authority
BR
Brazil
Prior art keywords
compounds
tocopherol
modified therapeutic
therapeutic drugs
formulations
Prior art date
Application number
BRPI0415858-0A
Other languages
English (en)
Inventor
Yuhua Zhang
Lynn C Gold
Original Assignee
Sonus Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sonus Pharma Inc filed Critical Sonus Pharma Inc
Publication of BRPI0415858A publication Critical patent/BRPI0415858A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTOS DE MEDICAMENTOS TERAPêUTICOS MODIFICADOS POR TOCOFEROL". Compostos de medicamentos terapêuticos modificados por tocoferol; emulsão, microemulsão e formulações de micela que incluem os compostos; métodos para fazer os compostos e formulações; métodos para administrar os compostos e formulações; e métodos para tratar condições usando os compostos e formulações.
BRPI0415858-0A 2003-10-29 2004-10-29 compostos de medicamentos terapêuticos modificados por tocoferol BRPI0415858A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US51536403P 2003-10-29 2003-10-29
US55613704P 2004-03-24 2004-03-24
US55876204P 2004-04-01 2004-04-01
US62165504P 2004-10-26 2004-10-26
PCT/US2004/036127 WO2005042539A1 (en) 2003-10-29 2004-10-29 Tocopherol-modified therapeutic drug compounds

Publications (1)

Publication Number Publication Date
BRPI0415858A true BRPI0415858A (pt) 2007-01-09

Family

ID=34557676

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415858-0A BRPI0415858A (pt) 2003-10-29 2004-10-29 compostos de medicamentos terapêuticos modificados por tocoferol

Country Status (12)

Country Link
US (3) US7223770B2 (pt)
EP (1) EP1682552B1 (pt)
JP (1) JP2007509978A (pt)
KR (1) KR20060110872A (pt)
AT (1) ATE472551T1 (pt)
AU (1) AU2004285037B2 (pt)
BR (1) BRPI0415858A (pt)
CA (1) CA2543722C (pt)
DE (1) DE602004027936D1 (pt)
IL (1) IL175158A0 (pt)
TW (1) TW200522978A (pt)
WO (1) WO2005042539A1 (pt)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
JP4891912B2 (ja) * 2004-11-05 2012-03-07 サムヤン コーポレイション 非水性極性溶媒中の１０−ヒドロキシカンプトテシン化合物の溶解度を増加させるための薬剤製剤
GT200500310A (es) * 2004-11-19 2006-06-19 Compuestos organicos
PT1853250E (pt) 2005-02-18 2012-02-03 Abraxis Bioscience Llc Combinações e modos de administração de agentes terapêuticos e terapia de combinação
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
KR101430767B1 (ko) * 2005-07-18 2014-08-19 유니버시티 오브 메사츄세츠 로웰 나노에멀젼 조성물 및 이의 제조 및 사용 방법
AU2016244292A1 (en) * 2005-07-18 2016-11-03 University Of Massachusetts Lowell Compositions and methods for making and using nanoemulsions
WO2007035311A2 (en) * 2005-09-16 2007-03-29 University Of Massachusetts Lowell Anti-oxidant synergy formulation nanoemulsions to treat cancer
US7744856B2 (en) * 2005-10-03 2010-06-29 Biotech Research And Development Corporation Formulations with feruloyl glycerides and methods of preparation
US7727514B2 (en) * 2005-10-03 2010-06-01 Biotechnology Research & Development Corporation Compositions comprising a UV-absorbing chromophore
US7572610B2 (en) * 2005-10-03 2009-08-11 Biotechnology Research & Development Corporation Methods of making compositions comprising a UV-Absorbing chromophore
ES2710781T3 (es) 2005-12-01 2019-04-26 Univ Massachusetts Lowell Nanoemulsiones de botulinum
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US7786134B2 (en) * 2005-12-16 2010-08-31 Sonus Pharmaceuticals, Inc. Lipophilic anticancer drug compounds, compositions and related methods
CZ300305B6 (cs) * 2005-12-20 2009-04-15 Heaton, A. S. Farmaceutická kompozice obsahující derivát taxanu se zlepšenou terapeutickou úcinností
US20070167422A1 (en) * 2006-01-18 2007-07-19 Yu Kwok S Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
TWI376239B (en) * 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
AU2007264975A1 (en) * 2006-06-29 2008-01-03 Biotech Research And Development Corporation Formulations with feruloyl glycerides and methods of preparation
US20100183726A1 (en) * 2006-08-02 2010-07-22 Robert Nicolosi Compositions and methods for treating cancer with dacarbazine nanoemulsions
KR20150028308A (ko) 2006-12-01 2015-03-13 안테리오스, 인코퍼레이티드 펩티드 나노입자 및 이의 용도
JP2010528981A (ja) 2006-12-01 2010-08-26 アンテリオス， インコーポレイテッド 両親媒性実体ナノ粒子
CN101765423B (zh) 2007-05-31 2014-08-06 安特里奥公司 核酸纳米粒子和其用途
CA2686225A1 (en) * 2007-06-22 2008-12-31 Scidose Llc Solubilized formulation of docetaxel without tween 80
CN101878024B (zh) * 2007-11-28 2014-04-09 塞拉特药物股份有限公司 改良的紫杉烷递送系统
CN107080734B (zh) 2008-03-20 2020-10-30 维尔恩公司 包含生育酚的peg衍生物的乳剂
EP2268274B1 (en) 2008-03-20 2012-05-16 Virun, Inc. Vitamin e derivatives and their uses
US7670894B2 (en) * 2008-04-30 2010-03-02 Intel Corporation Selective high-k dielectric film deposition for semiconductor device
BRPI0914630A2 (pt) * 2008-06-26 2019-09-24 Anterios Inc liberação dérmica
WO2010124223A1 (en) * 2009-04-23 2010-10-28 First Tech International Limited Anti-cancer tocotrienol analogues and associated methods
WO2011028757A1 (en) * 2009-09-01 2011-03-10 First Tech International Limited Tocotrienol compositions
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
WO2011097481A1 (en) * 2010-02-05 2011-08-11 First Tech International Limited Tocotrienol esters
WO2011103512A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha free fatty acid emulsions
KR101622441B1 (ko) * 2010-03-23 2016-05-18 버런, 아이엔씨. 자당 지방산 에스테르를 포함하는 나노에멀전
CA2794147A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma
MX364637B (es) 2010-03-29 2019-05-03 Abraxis Bioscience Llc Star Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc.
KR20190130050A (ko) 2010-06-04 2019-11-20 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
US8741373B2 (en) 2010-06-21 2014-06-03 Virun, Inc. Compositions containing non-polar compounds
EP2606910B1 (en) * 2010-08-20 2018-10-17 National University Corporation Tokyo Medical and Dental University Pharmaceutical composition for transcolonic absorption
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
CN102516258B (zh) * 2011-11-11 2014-06-25 正大天晴药业集团股份有限公司 水溶性维生素e衍生物修饰的脂溶性抗癌药物化合物和制剂、该化合物的制备方法及应用
WO2013120025A1 (en) 2012-02-10 2013-08-15 Virun, Inc. Beverage compositions containing non-polar compounds
CN102731518B (zh) * 2012-06-26 2014-12-03 济南精合医药科技有限公司 用于抗肿瘤药物的邻硝基芳甲氧基喜树碱缺氧激活前药
CN102731519B (zh) * 2012-06-26 2014-12-17 济南精合医药科技有限公司 用于抗肿瘤药物的对硝基芳甲氧基喜树碱缺氧激活前药
US9382187B2 (en) 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9351517B2 (en) 2013-03-15 2016-05-31 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and compositions containing same
US20140314672A1 (en) * 2013-04-06 2014-10-23 Igdrasol, Inc. Nanoparticle therapeutic agents, their formulations, and methods of their use
US20150147382A1 (en) * 2013-09-23 2015-05-28 Exir Nano Sina Company Topical liposomal compositions for delivering hydrophobic drugs and methods preparing same
WO2015171516A1 (en) 2014-05-05 2015-11-12 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
US10172961B2 (en) 2014-05-07 2019-01-08 Cornell University Inhibitors of fusion between viral and cell membranes as well as compositions and methods of using them
MX2016016830A (es) 2014-06-18 2017-07-07 Thetis Pharmaceuticals Llc Complejos de aminoacidos minerales de agentes activos.
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
US9861611B2 (en) 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
US10071112B2 (en) 2014-10-08 2018-09-11 Epigenetics Pharma Llc Vitamin E-nucleoside prodrugs
CN105777770B (zh) * 2014-12-26 2018-05-25 中国人民解放军第二军医大学 一种饱和长链脂肪酸修饰的7-乙基-10-羟基喜树碱化合物及其长循环脂质体
CN104800858B (zh) 2015-04-27 2017-11-21 中国医学科学院基础医学研究所 Hsp90抑制肽偶联物及其在肿瘤治疗中的应用
GB2550346B (en) * 2016-05-13 2021-02-24 Phytoceutical Ltd Micelles
DK3454907T3 (da) 2016-06-03 2020-10-19 Thetis Pharmaceuticals Llc Sammensætninger og fremgangsmåder relateret til salte af specialiserede pro-løsningsmediatorer af inflammation
CN110225975A (zh) 2016-08-23 2019-09-10 阿库斯股份有限公司 用于治疗人受试者中非年龄相关的听力损害的组合物和方法
WO2018093465A1 (en) 2016-11-21 2018-05-24 Eirion Therapeutics, Inc. Transdermal delivery of large agents
AU2019344783A1 (en) * 2018-09-17 2021-04-08 The Children's Hospital Of Philadelphia Polymer-based macromolecular prodrugs
AU2021225035A1 (en) 2020-02-21 2022-10-13 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
CA3231432A1 (en) 2021-10-15 2023-04-20 Tianyi Ke Composition containing antitumor drug, and preparation method therefor and use thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1395994A (en) * 1972-08-23 1975-05-29 Delmar Chem Tocopherol derivative processes for making it and pharmaceutical compositions containing it
GB1409612A (en) * 1973-09-13 1975-10-08 Ahrens G W Phenylpropyl-d-alpha-tocopherol-succinate the method for making the same and preparations
JPS5484034A (en) * 1977-12-16 1979-07-04 Nisshin Flour Milling Co Ltd Anti-tumor agent
US4320141A (en) * 1977-12-16 1982-03-16 Yasuhiro Komatsu Antitumor agent
US4665204A (en) 1985-06-27 1987-05-12 Henkel Corporation Diester derivatives of tocopherol
US5610180A (en) 1988-01-29 1997-03-11 Virginia Commonwealth University Ionizable congeners of aromatic and aliphatic alcohols as anti-leukemia agents
US5234695A (en) 1990-07-24 1993-08-10 Eastman Kodak Company Water dispersible vitamin E composition
JP3644543B2 (ja) 1993-10-22 2005-04-27 ヘクサル・アーゲー シクロスポリンＡ及びα−トコフェロールを含有する医薬組成物
GB9409778D0 (en) 1994-05-16 1994-07-06 Dumex Ltd As Compositions
CA2148148A1 (en) 1994-05-20 1995-11-21 Kazumi Ogata Tocopherol derivatives
DE4423915A1 (de) * 1994-07-07 1996-01-11 Carl Heinrich Dr Weischer Derivate des Salazosulfapyridins, deren Herstellung und Verwendung als Arzneimittel
US5858398A (en) 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
US5945409A (en) 1995-03-10 1999-08-31 Wilson T. Crandall Topical moisturizing composition and method
US5912078A (en) * 1996-05-02 1999-06-15 Milliken & Company Lubricant finish for textiles
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
DK0914116T3 (da) 1996-05-22 2000-11-20 Protarga Inc Kompositstoffer omfattende konjugater af cis-docosahexaensyre og Taxotere
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
EP0937082A2 (en) * 1996-07-12 1999-08-25 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
US5891469A (en) 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
US6727280B2 (en) 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
GB9715759D0 (en) * 1997-07-26 1997-10-01 Danbiosyst Uk New emulsion formulations
WO1999025729A1 (fr) 1997-11-18 1999-05-27 Chugai Seiyaku Kabushiki Kaisha Composes possedant une activite antitumorale
US5917060A (en) 1997-12-17 1999-06-29 Basf Aktiengesellschaft Preparation of chromanyl derivatives
DE69805334T2 (de) 1997-12-24 2002-12-05 Senju Pharmaceutical Co., Ltd. Derivate des vitamin e
US6086915A (en) * 1998-04-01 2000-07-11 Bioresponse L.L.C. Compositions and methods of adjusting steroid hormone metabolism through phytochemicals
CA2345079C (en) 1998-09-23 2011-06-21 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
US6045826A (en) 1999-04-02 2000-04-04 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
MXPA01011981A (es) * 1999-05-24 2003-09-04 Sonus Pharma Inc Vehiculo de emulsion para farmacos poco solubles.
EP1208150A4 (en) * 1999-06-11 2005-01-26 Sydney Hyman IMAGE FORMING MATERIAL
AU7719100A (en) * 1999-09-27 2001-04-30 Panayiotis Constantinides Compositions of tocol-soluble therapeutics
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
WO2002076970A2 (en) * 2001-03-23 2002-10-03 Sonus Pharmaceuticals, Inc. Tocopherol succinate derivatives and compositions
US6774116B2 (en) 2001-04-17 2004-08-10 Cryolife, Inc. Prodrugs via acylation with cinnamate
US6858227B1 (en) * 2001-11-21 2005-02-22 Sonus Pharmaceuticals, Inc. Vitamin E conjugates
US6683194B2 (en) 2002-02-05 2004-01-27 Sonus Pharmaceuticals, Inc. Tocopherol derivatives

Also Published As

Publication number Publication date
US20050096340A1 (en) 2005-05-05
AU2004285037B2 (en) 2010-07-22
US20070207196A1 (en) 2007-09-06
KR20060110872A (ko) 2006-10-25
ATE472551T1 (de) 2010-07-15
EP1682552A1 (en) 2006-07-26
EP1682552B1 (en) 2010-06-30
US20060229359A1 (en) 2006-10-12
CA2543722A1 (en) 2005-05-12
TW200522978A (en) 2005-07-16
CA2543722C (en) 2011-01-04
AU2004285037A1 (en) 2005-05-12
WO2005042539A1 (en) 2005-05-12
DE602004027936D1 (de) 2010-08-12
IL175158A0 (en) 2006-09-05
US7223770B2 (en) 2007-05-29
JP2007509978A (ja) 2007-04-19

Similar Documents

Publication Publication Date Title
BRPI0415858A (pt) compostos de medicamentos terapêuticos modificados por tocoferol
CY1109661T1 (el) 5-cnac ως παραγοντας για χορηγηση απο το στομα τμηματων παραθορμονης
EA200501702A1 (ru) Устойчивая к манипуляциям дозировочная форма для трансдермального введения
TW200603831A (en) Cholesterol/bile acid/bile acid derivative-modified therapeutic drug compounds
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
UY26130A1 (es) Compuestos para tratar la obesidad
DE602005010788D1 (de) Pharmazeutische Zusammensetzungen zur sicheren Verabreichung von bei der Behandlung von Drogenabhängigkeit verwendeten Arzneimitteln
ATE450252T1 (de) Arzneimittel-mikroteilchen
NO20055173L (no) Farmasoytisk kombinasjonsblanding omfattende modafinil og et annet legemiddel
CY1113462T1 (el) Μορφη δοσολογιας περιεχουσα παντοπραζολη ως δραστικο συστατικο
CY1107074T1 (el) Συνθεση εναντιομερων 4-αμινο-θαλιδομιδης
CY1106386T1 (el) Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης
EA200601846A1 (ru) Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей
ATE550015T1 (de) Verfahren und zusammensetzung zur behandlung von rhinitis
CY1108401T1 (el) Παραγωγα πυρρολοϊμιδαζολης, η παρασκευη τους, φαρμακευτικες συνθεσεις που τα περιεχουν και η χρηση τους ως νοοτροπικων παραγοντων
CY1107231T1 (el) Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
DE69626544D1 (de) Arzneistoffe
DK1492539T3 (da) Statin-terapi til forögelse af kognitiv funktion
EP1603595A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRUG INDEPENDENCE
NO20075508L (no) Stannsoporfinpreparater og administrering
SE0203817D0 (sv) New composition
SE0101258D0 (sv) Treatment of low back pain and whiplash associated disorder
WO2005011589A3 (en) Drug delivery methods and devices

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.